In summary, on the basis of our here presented experience, we think that sorafenib—or other FLT3 inhibitors—in combination with chemotherapy is an adequate treatment option for cytoreduction in AML FLT3-ITD hyperleukocytosis. The gene discussed is FLT3; the disease is acute myeloid leukemia.